Teriparatide biosimilar is under clinical development by TSH Biopharm and currently in Phase I for Osteoporosis.

VS-105 is under development for the treatment of osteoporosis, secondary hyperparathyroidism in chronic kidney disease, inflammatory bowel disease, psoriasis. It is administered through oral route. VS ...

More Australian women come forward with concerns about serious side effects from the popular contraceptive Depo-Provera, with many claiming they were not made aware of the risks of the high-dose ...

Winter poses additional risks for osteoporosis sufferers, with cold weather exacerbating bone and joint issues. Preventative ...

Age-related bone loss occurs independently of the gut microbiome, a surprising revelation that challenges prior assumptions.

Osteoporosis, characterized by an imbalance in bone remodeling, is a growing health concern worldwide. Previous research has ...

Osteoporosis, characterized by an imbalance in bone remodeling, is a growing health concern worldwide. Previous research has ...

Age-related bone loss occurs independently of the gut microbiome, a surprising revelation that challenges prior assumptions. By analyzing bone health ...

Osteoporosis, often described as a "silent disease," is characterized by weakened and brittle bones that become increasingly prone to fractures. This condition ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The Osteoporosis Therapeutics market value was US$ $$ billion in 2021. The Osteoporosis Therapeutics market value is forecast to reach US$ $$ billion by 2031, growing at a compound annual growth rate ...